Virpax Pharma rises after promising pre-clinical pain therapy data

Virpax Pharmaceuticals

08/12/2021 16:32

** Pain drug developer's  VRPX.O  shares jumps ~10% to $4.47
    ** Co reports positive results from a study on one of its
lead experimental drugs, Epoladerm, for the management of pain
associated with osteoarthritis of the knee 
    ** Single-dose of Epoladerm directly delivered through the
skin was well-tolerated in all minipigs in pre-clinical studies,
with no treatment-related changes in body weight or skin
irritation observed  urn:newsml:reuters.com:*:nBwbFRK08a 
    ** The data would support Virpax's application to the U.S.
FDA to begin human trials for Epoladerm - co
    ** Shares trading above their 50-day moving average price
    ** Including session moves, stock has fallen ~31% since its
Feb. 17 debut  

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))